Demand for intragastric balloons is forecast to increase from USD 156.2 million in 2026 to USD 468.2 million by 2036, registering an 11.6% CAGR over the forecast period. Fact.MR attributes this expansion to increasing adoption of weight management treatments, improvements in balloon technologies, and expanding healthcare distribution infrastructure. The market was valued at approximately USD 140.0 million in 2025 and is expected to generate an absolute dollar opportunity of USD 312.0 million between 2026 and 2036.

Healthcare providers are increasingly evaluating intragastric balloon systems as part of non-surgical weight management programs. Product quality, regulatory compliance, and clinical requirements are influencing purchasing decisions across hospitals and specialty clinics. Improvements in device design and wider distribution networks are also supporting adoption in developing healthcare markets, where institutional investment is creating new opportunities for manufacturers.

Get detailed market forecasts, competitive benchmarking, and pricing trends:

https://www.factmr.com/connectus/sample?flag=S&rep_id=11476

Single Balloon Systems Retain Dominant Market Position

By product type, single balloon systems are expected to account for 58% of the intragastric balloons market in 2026. Their established presence, competitive pricing, and broad applicability across weight management procedures support continued demand. Strong distribution networks and institutional procurement relationships also contribute to their leading position.

Gas-filled balloons and dual balloon systems represent additional product categories serving different clinical and purchasing requirements. Gas-filled balloons are attracting interest as manufacturers improve product performance and cost efficiency. Demand for alternative balloon configurations is also influenced by the availability of specialized treatment options and evolving institutional preferences.

Weight loss management represents the largest application segment, projected to capture 64% of the market in 2026. The segment benefits from established clinical demand and the availability of intragastric balloon systems designed for non-surgical weight reduction. Pre-bariatric surgery and metabolic disorder management represent other applications covered in the report.

Hospitals are expected to account for 46% of end-use demand in 2026. Their leading position reflects established clinical workflows, institutional purchasing arrangements, and access to specialized treatment departments. Specialty clinics and ambulatory surgical centers also contribute to demand as healthcare providers expand their weight management services.

India, Germany, and the UK Show Growth Opportunities

India is projected to record a 13.1% CAGR from 2026 to 2036, making it the fastest-growing country among those assessed in the report. Expanding healthcare infrastructure, increasing institutional demand, and rising adoption across public and private healthcare facilities are supporting market development. Cost-competitive manufacturing and improving distribution capabilities are also creating opportunities for domestic suppliers and international manufacturers.

Germany is expected to advance at a 10.9% CAGR during the same period. Established institutional purchasing systems, rigorous quality requirements, and a developed healthcare infrastructure support demand for intragastric balloon technologies. Manufacturers operating in Germany must address product performance expectations and regulatory compliance requirements. Cross-border distribution within the European Union also provides opportunities to serve additional regional markets.

The United Kingdom is forecast to register a 9.8% CAGR through 2036. The report identifies the UK as one of the European countries contributing to regional market expansion. Demand across Europe is supported by established regulatory frameworks, institutional purchasing arrangements, and distribution networks serving healthcare providers.

The broader market is also influenced by developments in China and the United States. China is expected to grow at a 12.8% CAGR, supported by expanding domestic demand, manufacturing capabilities, and institutional procurement. The United States is projected to register an 11.5% CAGR as established healthcare purchasing networks and regulatory frameworks support continued market activity.

Competitive Landscape

Competition in the intragastric balloons market includes established medical device manufacturers with specialized product portfolios, institutional relationships, and international distribution capabilities. Key companies profiled by Fact.MR include Apollo Endosurgery, Inc., Obalon Therapeutics, Inc., Allurion Technologies, Inc., and ReShape Medical, Inc. Other companies covered include Spatz3, Helioscopie, MEDSIL, Endalis, Lexel Medical, Silimed, and BioEnterics.

Manufacturers are competing through product differentiation, regulatory compliance, distribution coverage, and institutional purchasing relationships. Hospitals and specialty clinics increasingly consider product quality, clinical suitability, supply reliability, and long-term commercial support when evaluating suppliers.

The report identifies the market as moderately consolidated, with established manufacturers benefiting from broader product coverage and procurement relationships. Smaller companies continue to compete through specialized offerings, regional distribution capabilities, and competitive pricing.

Technology and Regulatory Developments Shape the Market

The intragastric balloons market is undergoing changes in product design, clinical delivery methods, and purchasing requirements. Fact.MR identifies endoscopic placement technology, swallowable balloon technology, adjustable balloon systems, and safety-monitoring solutions as important technology categories.

Swallowable balloon systems offer an alternative product configuration within the broader market, while adjustable systems provide additional design options for treatment requirements. Safety and monitoring technologies, including leak detection and patient monitoring, remain relevant to product development and clinical use.

Regulatory requirements are also influencing commercial strategies. Manufacturers must address differing compliance frameworks across geographic markets, creating additional complexity in product introduction and distribution. Institutional buyers are placing greater emphasis on documented product performance, quality standards, and dependable supply arrangements.

Fact.MR reports that Apollo Endosurgery expanded its product portfolio in February 2026, while Obalon Therapeutics and Allurion Technologies recorded distribution or product developments during 2025. These reported activities reflect the importance of product innovation and geographic reach in maintaining competitive positions.

As healthcare providers expand weight management services and manufacturers develop more specialized balloon systems, regulatory readiness and distribution capabilities are expected to remain important competitive factors. The full Fact.MR report provides detailed market forecasts, segment analysis, country-level growth assessments, and competitive benchmarking through 2036.

Top Reports:

https://adamaamresearch.blogspot.com/2026/10/ferrous-sulfate-market-to-hit-usd-123.html

https://net-pals.com/blogs/61015/Ferrous-Sulfate-Market-2036-Forecast-USD-1-23-Billion-USA

https://acmingle.com/blogs/33546/Ferrous-Sulfate-Market-2036-Outlook-USA-3-3-Germany-2

https://ikofficial.com/blogs/61665/Ferrous-Sulfate-Market-2036-Projection-USD-1-23-Billion-Germany

About Fact.MR

Fact.MR is a market research and consulting company providing market intelligence, competitive analysis, and forecasting across global industries. Its research supports businesses with data-driven insights into emerging markets, technology trends, competitive dynamics, regional opportunities, and changing demand patterns.